Selank Dosage Guide

## Overdose Profile No cases of Selank overdose have been reported in the published medical literature. Given the peptide's pharmacological profile -- no respiratory depression, no direct opioid receptor activation, no sedation even at high doses -- the acute toxicity risk appears to be extremely low. ## Animal Data Preclinical studies conducted for Russian regulatory approval were unable to establish an LD50 through standard routes of administration, suggesting that the therapeutic index is exceptionally wide. Doses many times higher than the therapeutic range did not produce mortality or serious organ toxicity in rodent models. ## Theoretical Concerns at Excessive Doses While acute toxicity is unlikely, theoretically excessive doses could produce: - **Immunological effects** -- given Selank's cytokine-modulating properties, very high or chronic overdosing could theoretically dysregulate immune function, though this has not been observed - **Excessive enkephalin accumulation** -- if enkephalin-degrading enzymes are saturated, supraphysiological enkephalin levels could theoretically produce unintended effects, though the body's enkephalin system has robust autoregulatory mechanisms ## Practical Guidance In the unlikely event of significant overdose via intranasal or subcutaneous administration, no specific antidote exists or is likely necessary. Supportive observation is sufficient. The peptide will be rapidly degraded by endogenous peptidases and the effects will resolve spontaneously within hours.